Please assess the completion status of the following clinical trial:

Trial Title: DHEA Against Vaginal Atrophy - Safety Study of 12 Months

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~* Postmenopausal women (non-hysterectomized)~* Women between 40 and 75 years of age.~* Willing to participate in the study and sign an informed consent.~* Women who have self-identified symptom(s) of vaginal atrophy.~* Willing to have endometrial biopsy at screening and end of study (Week 52).~Main Exclusion Criteria:~* Undiagnosed abnormal genital bleeding.~* Hypertension equal to or above 140/90 mm Hg.~* The administration of any investigational drug within 30 days of screening visit.~* Endometrial hyperplasia, cancer or endometrial histology showing proliferative, secretory or menstrual type characteristics at histologic evaluation of endometrial biopsy performed at screening.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- DHEA (Type: EXPERIMENTAL): 0.5% DHEA (intravaginal)

Based on this trial design, predict the completion outcome and termination type (if applicable).